Trial Profile
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Voxelotor (GBT440) in Pediatric Participants With Sickle Cell Disease (HOPE Kids 2)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 21 Jan 2024
Price :
$35
*
At a glance
- Drugs Voxelotor (Primary)
- Indications Sickle cell anaemia
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms HOPE Kids 2
- Sponsors Global Blood Therapeutics
- 12 Dec 2023 Information of implementation of a standardized TCD screening protocol, presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 19 Jul 2023 Planned End Date changed from 1 Mar 2025 to 28 Jan 2025.
- 19 Jul 2023 Planned primary completion date changed from 1 Mar 2025 to 5 Sep 2023.